Cytokeratin 14/16 (S5) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
Cytokeratin 14/16 (S5) Peptide Applications :
Blocking Background :
In Bowen’s disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inheritied skin disorder characterized by skin blistering due to basal keratinocyte fragility.Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN). Alternative Name :
Keratin, type I cytoskeletal 14; Cytokeratin-14; Short name=CK-14; Keratin-14; Short name=K14; KRT14; CK-14; CK 14; CK14; Cytokeratin-14; Cytokeratin 14; Cytokeratin14; Keratin, type I cytoskeletal 16; Cytokeratin-16; Short name=CK-16; Keratin-16; Short name=K16; KRT16; KRT16A; CK-16; CK 16; CK16; Cytokeratin-16; Cytokeratin 16; Cytokeratin16; Swiss-Prot :
P02533/P08779 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Cytokeratin 14/16 (S5). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1200 Cytokeratin 14/16 (S5) pAb.
Cytokeratin 14/16 (S5) Peptide Applications :
Blocking Background :
In Bowen’s disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inheritied skin disorder characterized by skin blistering due to basal keratinocyte fragility.Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN). Alternative Name :
Keratin, type I cytoskeletal 14; Cytokeratin-14; Short name=CK-14; Keratin-14; Short name=K14; KRT14; CK-14; CK 14; CK14; Cytokeratin-14; Cytokeratin 14; Cytokeratin14; Keratin, type I cytoskeletal 16; Cytokeratin-16; Short name=CK-16; Keratin-16; Short name=K16; KRT16; KRT16A; CK-16; CK 16; CK16; Cytokeratin-16; Cytokeratin 16; Cytokeratin16; Swiss-Prot :
P02533/P08779 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Cytokeratin 14/16 (S5). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS1200 Cytokeratin 14/16 (S5) pAb.
Blocking peptide available as BS1200PP